Epazote Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
About Epazote Pharmaceuticals
Epazote Pharmaceuticals Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 September 2020 (Four years and five months 1 days old ). Its registered office is in Ambala, Haryana, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vimal Chopra and Satyam Chopra serve as directors at the Company.
Company Details
-
Location
Ambala, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24110HR2020PTC088888
-
Company No.
088888
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Sep 2020
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Epazote Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vimal Chopra
|
Director | 01-Sep-2020 | Current |
|
Satyam Chopra
|
Additional Director | 03-May-2023 | Current |
Financial Performance of Epazote Pharmaceuticals.
Epazote Pharmaceuticals Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Epazote Pharmaceuticals?
Unlock access to Epazote Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Glaxy-Gen Pharma Private LimitedVimal Chopra is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Epazote Pharmaceuticals?
Epazote Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Epazote Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Epazote Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
